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Background: The International Subarachnoid Aneurysm Trial (ISAT) demonstrated improved one-year clinical
outcomes for patients with ruptured intracranial aneurysms treated with endovascular coiling compared to surgical
clipping. Patients included in ISAT were mostly good grade subarachnoid hemorrhage (SAH) patients with small
anterior circulation aneurysms. The purported superiority of coiling is commonly extrapolated to patients not
studied in the original trial or to those treated using new devices not available at the time. Conversely, many
patients are treated by clipping despite ISAT, because they are thought either to be better candidates for surgery,
or to offer more durable protection from aneurysm recurrences. These practices have never been formally validated.
Thus, for many ruptured aneurysm patients the question of which treatment modality leads to a superior clinical
outcome remains unclear.
Methods/trial design: ISAT II is a pragmatic, multicenter, randomized trial comparing clinical outcomes for non-
ISAT patients with subarachnoid hemorrhage allocated to coiling or clipping. Inclusion criteria are broad. The
primary end-point is the incidence of poor clinical outcome (defined as mRS >2) at one year, just as in ISAT.
Secondary end-points include measures of treatment safety for a number of pre-specified subgroups, with efficacy
end-points including the presence of a major recurrence at one year; 1,896 patients (862 each arm plus 10% losses)
are required to demonstrate a significant difference between coiling and clipping, hypothesizing 23% and 30%
poor clinical outcome rates, for coiling and clipping, respectively. The trial should involve at least 50 international
centers, and will take approximately 12 years to complete. Analysis will be by intention-to-treat.
Trial registration: ISAT II is registered at clinicaltrials.gov: NCT01668563.
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To prevent re-bleeding from ruptured intracranial aneu-
rysms, subarachnoid hemorrhage (SAH) patients are
often treated by surgical clipping [1,2] or, in the last 20
years, endovascular coiling [3]. Very little randomized evi-
dence has guided clinical decision making in neurovascular
surgery since the early trials pioneered by McKissock [4]
until the publication of the International Subarachnoid
Aneurysm Trial (ISAT) in 2002. ISAT was a turning point
in modern neurosurgical history [5]. The trial showed that* Correspondence: tdarsaut@ualberta.ca
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reproduction in any medium, provided the orfor 2,143 SAH patients eligible for both surgery and
endovascular coiling recruited between 1994 and 2002,
randomized allocation to coiling was associated with bet-
ter one-year clinical outcomes defined as survival without
dependency (absolute risk reduction (ARR) of 7.4% (95%
CI: 3.6 to 11.2, P = 0.0001). Such a ground-breaking result
was bound to be received with some resistance, expressed
in multiple editorials and commentaries (reviewed in [6]).
However, because ISAT was a positive pragmatic trial, an
appropriate interpretation of the results was that coiling
should be adopted as the first-line treatment for ruptured
aneurysms, at least for patients with the types of lesions
included in ISAT. These were, for the great majority, small
(≤10 mm) anterior circulation aneurysms [6]. Although
ISAT was well designed, conducted, and reported, a singlel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trial results were perhaps inappropriately extrapolated be-
yond what ISAT demonstrated [7]. Coiling has progres-
sively replaced clipping in many centers, even for many
patients that would not have been studied in ISAT [7].
Unfortunately, there is no current evidence to support
coiling in the wide spectrum of non-ISAT patients and
aneurysms that are currently treated endovascularly.
A recent pre-randomized study of coiling as first-
intention confirmed better results for those ruptured
aneurysms felt to be readily coilable; however only 62% of
patients allocated to coiling were actually coiled, 38% were
crossed-over to be clipped [8]. Ten years following the
publication of ISAT, the optimal management of more
difficult-to-coil ruptured aneurysms remains unclear.
Multiple new devices have been introduced during the
last decade. This has expanded the spectrum of cases
that can be treated using endovascular techniques,
though no evidence is available to confirm that these
patients should not be clipped instead.
Angiographic recurrences (occurring in 10% to 33% of
patients [9-11]) has raised concerns that aneurysm
coiling may not be as durable in the long-term as surgical
clipping. ISAT patients allocated to coiling were more fre-
quently retreated (17%) than those allocated to clipping
(4%). However, clipped patients were not as rigorously
followed angiographically [12,13]. Retreatments were
much less frequent in the more recent Cerecyte (5.5%)
and HELPS trials (3%) [10,11]. Offering a more durable
protection from late re-bleeding is still a frequent reason
why many neurosurgeons continue to clip ruptured aneu-
rysms in spite of ISAT results. Furthermore, publication of
the 5-year follow-up data showed that the risk of death at
5 years was significantly lower with coiling (11% versus
14%; P = 0.03) but the proportion of survivors that were
independent did not differ between the two groups [12].
Although coiling is increasingly used in most coun-
tries, clinical practices vary tremendously, with some
centers coiling as low as 20% of ruptured aneurysms,
with other centers coiling upwards of 70% of ruptured
aneurysms [7,14-16], depending on training, local ex-
pertise, and preferences, as well as biased data from
non-randomized case series and registries [17]. Thus, for
many patients the uncertainty regarding the best choice
of treatment modality persists and another randomized
trial is needed to offer optimal care in the presence of
such uncertainty.
Methods: Trial design
ISAT II is a randomized, multicenter, pragmatic trial
comparing clinical outcomes for patients with ruptured
intracranial aneurysms treated with endovascular treat-
ment or with surgical clipping. All patients with ruptured
aneurysms who are still being considered for surgicalclipping in spite of ISAT results, and all those with rup-
tured aneurysms which were not well-represented in the
original ISAT study or for which the use of new devices
such as stents is contemplated, will be proposed participa-
tion in the trial. The study will be conducted in approxi-
mately 50 centers performing both surgical clipping and
endovascular coiling of aneurysms, after approval from
local ethics committees and with informed consent from
participating patients, aiming to enroll at least 10 patients
per year per center, and thus requiring approximately
10 years to recruit 1,896 patients. ISAT II will follow
the principles enunciated in the Declaration of Helsinki.
The complete protocol is available at www.clinical-care-
trials.org.
Primary hypothesis of ISAT II
Endovascular management of patients with ruptured,
intradural, intracranial aneurysms suitable for both
endovascular and surgical management, for whom the
treating physician remains unsure whether the results of
the original ISAT study apply, will lead to a decrease in
the number of poor outcomes (defined as modified rank-
ing scale (mRS) >2) from 30% to 23% at one year.
Study endpoints
The primary end-point, as for the original ISAT study,
will be the number of patients experiencing a poor clinical
outcome (mRS >2) at one year post-treatment. Secondary
end-points include overall mortality at one year (all
causes), overall morbidity at one year (all causes), occur-
rence of a major (saccular) aneurysm recurrence at one
year post-treatment, peri-treatment hospitalization lasting
more than 15 days, discharge to a location other than
home, occurrence of an intracranial hemorrhage after en-
rollment and for up to one year, occurrence of aneurysm
re-rupture following randomization but before treatment
initiation, and occurrence of failure of aneurysm occlusion
using the intended treatment modality.
Planned trial interventions
Surgical clipping or endovascular coiling is performed
once for each patient. In the setting of multiple aneu-
rysms, more than one aneurysm can be treated in the
same sitting. Treatment will be initiated as soon as pos-
sible given local logistical constraints, according to
standard of care of patients with ruptured aneurysms.
Aneurysms thought by the treating teams to require de-
liberate permanent parent vessel occlusion, construction
of a surgical bypass, or other flow-redirecting treatments
that do not directly clip the aneurysm will not be
excluded; these non-ISAT aneurysms are expected to be
more difficult to manage with either surgical or endo-
vascular methods.
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Inclusion criteria
Patients at least 18 years of age; at least one documented,
intradural, intracranial aneurysm, ruptured within last 30
days; SAH World Federation of Neurological Surgeons
(WFNS) grade 4 or less; the patient and aneurysm are
considered appropriate for either surgical or endovascular
treatment by the treating team.
Exclusion criteria
Patients with absolute contraindications of administration
of contrast material (any type); patients with arteriovenous
malformation-associated aneurysms; aneurysm located at
basilar apex.
ISAT II will be a pragmatic trial; inclusion criteria will
be kept loose and exclusion criteria minimal. The intent
of ISAT II is not to repeat the initial ISAT. We expect
ISAT II patients to be those for whom patient or
aneurysm-related characteristics would not have led to
their inclusion in ISAT, but for whom endovascular
treatment is now contemplated. In other words, we are
aiming to enroll patients to whom the global results of
ISAT may not directly apply. As a general rule, patients
previously referred to clipping despite the results of
ISAT should now be considered for ISAT II. Similarly,
patients considered for coiling, but with the assistance of
devices that were not used in the original ISAT trial,
such as stents, should be considered for ISAT II.
One exception in our pragmatic policy of as few exclu-
sion criteria as possible is that we have chosen to ex-
clude basilar apex aneurysms from the ISAT II study.
Especially in the current climate, where surgical expertise
with ruptured aneurysms in this notoriously challenging
location is disappearing, this means the majority of
ruptured aneurysms in this location will be treated with
endovascular methods.
Method of allocation
After confirmation of inclusion and exclusion criteria,
patients will be randomly allocated 1:1 to either surgical
or endovascular management, using a centralized
minimization procedure. The following factors will be
balanced between groups: i) age ≥70; ii) WFNS grade >3;
iii) aneurysm size ≥10 mm (using maximum aneurysm
diameter on cross-sectional imaging, with the outer
diameter used for partially thrombosed aneurysms); and
iv) posterior circulation location. The entire randomization
procedure will be performed using a web-based platform
available 24 hours a day.
Justification of minimization criteria
Patient age
Subgroup analyses from ISAT point to a potential benefit
from surgery in patients older than 70, who overall doworse than younger patients, whether they are treated one
way or another. To ensure that this risk factor remains
balanced between treatment groups, we have included age
≥70 (date of randomization on or beyond 70th birthdate)
as a minimization criterion.
SAH grade
Patients with Grade V aneurysm rupture, with a high
mortality rate, will be excluded. Initial SAH grade is pre-
dictive of outcome [18-21]. Thus we will balance the
number of poor (WFNS IV) grade SAH patients in each
group.
Aneurysm size
Aneurysms 10 mm or larger may have greater treatment-
associated risks, as well as a greater risk of incomplete
occlusion and/or recurrence [18,22-25].
Aneurysm location: middle cerebral artery bifurcation and
posterior circulation
Posterior circulation aneurysms have been associated
with worse prognosis for both clipping and coiling [5].
For this reason, lesions in the different circulations will
be minimized to ensure balanced groups, although we
expect posterior circulation aneurysms will represent a
minority of patients. Middle cerebral artery (MCA) an-
eurysms are common, but they were under-represented
in ISAT. While they are increasingly treated with coiling,
the best option remains unknown. We will monitor clin-
ical results of treatments of MCA aneurysms separately,
but this location will not be a minimization criterion.
Anticipated use of adjunct devices
These devices are likely to be used in more difficult le-
sions; they necessitate the addition of a double antiplatelet
regimen that may increase risks when aneurysms are
treated in the early phase of SAH [26-28]. Results in this
group will be monitored separately, but anticipated use of
an adjunct device will not be a minimization criterion.
Number of patients
With target alpha 0.05 and power 90%, a sample size of
1,724 patients (862 per group, no losses) would be suffi-
cient to demonstrate a significant difference, using esti-
mated 23% and 30% poor clinical outcome rates for
endovascular treatment (EVT) and surgical management
at one year, respectively (two-sided Fisher’s exact test).
We expect very few losses to follow-up (<10%), and the
target sample size is 1,896 patients.
Planned patient follow-up
All patients will be seen in clinic at six to eight weeks, as
part of routine follow-up care, followed by a telephone
call at six months and another routine clinic visit at one
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and to inquire about possible aneurysm re-rupture. All
patients will have non-invasive imaging (CTA or MRA)
at six months to one year post-treatment to determine
the presence of a major, saccular aneurysm recurrence.
This follow-up is considered to be standard of care.
There will be a study phone interview at five years to
optimize long-term follow-up (Table 1).
Planned analyses
The main statistical tests will involve comparisons be-
tween the probability of reaching the primary end-point
(dependent survival or death at one year) with a surgical
or endovascular management strategy. Descriptive statis-
tics will be done on demographic variables and potential
risk factors to compare the two groups at baseline. Means,
standard deviations, and ranges will be presented for
quantitative variables such as size of aneurysms and fre-
quency tables for categorical variables (such as the num-
ber of patients with multiple aneurysms). Statistics will be
broken down by center and by treatment arm. Compari-
son of the groups will be assessed through independent
ANOVA (quantitative data) or Mantel-Haentzel and χ2
tests (categorical data). Assuming comparability of groups
across centers, the primary outcome will be compared be-
tween groups using a Fisher’s exact test at one year.
Secondary outcomes will be compared using inde-
pendent t-tests for quantitative variables and χ2 tests for
categorical variables. The analyses of follow-up data will
control for baseline data using logistic regression,
ANCOVA or Cox regression multivariate methods. All
tests will be interpreted with a 0.05 level of confidence.
Stratification of results
Clinical outcomes will be stratified according to the
minimization criteria. The Data and Safety MonitoringTable 1 Schedule of evaluations
Evaluation Screening Pre-entry Entr






Failure to occlude aneurysm
Number of days in hospital
Discharge disposition
Major (saccular) aneurysm recurrence
Hemorrhage during FU
Telephone interview
*Including catheter angiography or non-invasive imaging.Board (DSMB) will regularly verify that subgroup treat-
ment outcomes are within the confidence intervals of
the study hypotheses.
Ethics approval
The Health Research Ethics Board of the University of
Alberta approved the protocol on October 1st, 2012
(Study ID: Pro00032613), the Institutional Review Board
of the Centre Hospitalier de l’Université de Montréal
approved the protocol on October 22nd, 2012 (Study ID:
12.136). Secondary approval will be sought from all local
ethics committees. Based on the Declaration of Helsinki,
written informed consent will be obtained from each
participating patient or appropriate surrogate in oral and
written form prior to enrollment. The ISAT II study is
registered with ClinicalTrials.gov: NCT01668563.
Discussion
In many centers, the consequences of the positive results
of the original ISAT study was that endovascular
ruptured aneurysm treatment was given the right of first
refusal for all aneurysms, and all patients. Proponents of
endovascular therapy often assert that the technology
(and thus outcomes) will have improved since ISAT,
which was interrupted more than 10 years ago, for the
benefit of all patients. Not only has this never been
proven, there is reason to fear that extrapolation of ISAT
results to many patients that would not have been
included in the original trial could lead to clinical out-
comes that may be inferior to surgery. Although we have
designed ISAT II as a pragmatic trial, the intent is not to
repeat ISAT. Our aim is to provide optimal care to those
patients for whom clipping may still be the best option,
although this is once more only a hypothesis that must
be trialed against the new generalization that coiling, in
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BRAT trial, is possible, we have chosen a classical de-
sign, with randomization only after clinicians have con-
sidered the patient eligible for both treatment options,
explained both alternatives, and obtained inform consent
[8]. The issue of ‘equipoise’ that could, if too narrowly
understood, excessively limit recruitment is acknowledged,
but other designs such as Zelen’s [29] raise additional
ethical issues that we preferred to avoid.Questions that remain unanswered after ISAT
Patients for whom major uncertainty persists can be
defined by using three overlapping categories: i) patients
that were excluded from the original ISAT study, for lack
of ‘equipoise’ at the time; ii) patients for whom there is
an a priori clinical reason to suspect results could be dif-
ferent from overall trial outcomes, but for whom ISAT
subgroup analyses could not provide sufficient power to
support a definitive conclusion; iii) patients that can
now be treated using an endovascular approach as a
result of the availability of new devices that were not
available at the time of ISAT.Patients excluded from ISAT
More than 9,559 aneurysms were screened, but only
2,143 patients were enrolled in the original ISAT study
[5]. The applicability of the study results to the type of
patients that were screened but excluded remains in
doubt. Subgroup analyses show that a variety of aneu-
rysms and clinical situations were under-represented in
the original ISAT study [30]. MCA bifurcation aneu-
rysms are readily accessible by surgery, while their anat-
omy may sometimes be less favorable for simple coiling,
at least during the years that ISAT was conducted. MCA
aneurysms were likely excluded because they were pref-
erentially clipped. Due perhaps to perceived difficulties
with surgical access, an insufficient number of posterior
circulation aneurysm (only 2.7% of the total number)
were included in ISAT. Posterior circulation aneurysms,
and especially basilar bifurcation aneurysms, were likely
preferentially coiled [31]. As a result, a substantial num-
ber of clinicians remain unsure about the best manage-
ment of MCA and of non-basilar, posterior circulation
aneurysms.Patients for whom subgroup analyses remain
unconvincing
Subgroup analyses are notoriously potentially misleading
[32], however, they can be used to help formulate
hypotheses for a new trial, especially when there are a
priori reasons to suspect that results in certain sub-
groups may differ from the overall results.Patient age
Subgroup analyses from ISAT point to an interaction
with age (P = 0.04), with a potential benefit from surgery
in patients older than 70 (RR: 1.15 (0.82, 1.61)). In youn-
ger patients, surgeons may be tempted to clip a ruptured
aneurysm because the benefits of coiling may be smaller
(RR: 0.91 (0.59, 1.39), while clipping may promise a
lower risk of recurrence [33]. Younger patients (<40 years
of age) have greater remaining life expectancy during
which their risk of developing an aneurysm recurrence
may be greater, while older patients (>70 years old) may
have heightened treatment-related risks with either
modality, with increased surgical risks, as well as more
difficult and risky endovascular access.
Location
Subgroup analyses of ISAT showed an interaction with
location (P = 0.01). Only 14.1% of aneurysms in the
original ISAT were located on the MCA, likely because
lesions in this location were preferentially treated surgi-
cally. Despite this selection, the subgroup analysis
showed similar results for coiling and clipping (RR: 1.01
(0.71, 1.45)). Today, many more MCA aneurysms are
coiled, often with adjunctive balloons and stents. Are
these patients really better served with endovascular
rather than surgical treatment?
Aneurysm size
Subgroup analyses of ISAT failed to show an interaction
with aneurysm size (P = 0.4), and results for aneurysms
larger than 10 mm were similar (RR: 0.96 (0.65, 1.42)).
The rate of aneurysm recurrence increases as aneurysm
size increases [9], and many clinicians are tempted to
use stents or to treat large aneurysms with clipping, in
spite of the ISAT overall results.
Patients now treated via an endovascular strategy with
new devices
Proponents of endovascular treatment sometimes justify
expanding the indications of the endovascular approach
on the basis of improved catheter and coil technology,
although this presumption has never been reliably
demonstrated. The increasing use of stents and, more
recently flow-diverters, which were not tested in ISAT,
may increase endovascular treatment risks; they require
the additional use of a dual anti-platelet agent regimen to
prevent subacute thrombotic complications, which can in
turn increase risks of re-bleeding and hemorrhagic com-
plications of ventricular drainage [26,34,35]. These devices
may expand indications of EVT to wide-neck aneurysms
that would not have been included in ISAT. The wider
spectrum of patients and aneurysms now considered for
EVT may not all experience the benefit seen in the ori-
ginal ISAT trial [6]. The relatively small ARR of 7.4%
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the potential risks due to stents are considered.
Other considerations often influence treatment choices.
Certain patients may carry a higher risk with endovascular
management: very small (<4 mm) aneurysms [35,36] or
wide-neck (>4 mm) aneurysms [26] (or any lesion whose
treatment may require a stent) have been shown, in case
series, to carry increased risks [26]. For these aneurysms,
the relatively small advantage demonstrated in ISAT
may not apply to current patients facing the dilemma of
trying to choose the best treatment modality. On the
other hand, some clinical situations may be more favor-
able to surgical management. This includes patients
presenting with a large but non-life threatening
intraparenchymal hematoma, or those with multiple
aneurysms accessible through one craniotomy. Many
questions regarding when coiling or clipping is appro-
priate remain, and a number of patients are proposed
surgery, despite ISAT, and all without convincing evi-
dence. On the other hand many patients are proposed
EVT, using devices that have never shown superiority to
clipping. Clinicians are presently forced to make case-
by-case decisions based on unreliable estimates of the
respective risks and benefits of each intervention. A
more prudent, systematic approach is in order. The es-
sence of scientific medicine is to question the hypoth-
eses behind our as-of-yet not validated actions. We
believe we need another pragmatic trial, which is the best
way to offer the best possible care in the presence of
uncertainty [37].
When should trials be interrupted?
If so much uncertainty remains after ISAT, one may ask,
at least in retrospect, why was this successful, inter-
national collaboration interrupted? Why did the SAH
patient randomization process, finally under way in
ISAT, not simply continue? The difficult-to-initiate
process of randomizing SAH patients could easily have
continued in participating centers, with a more refined
question, immediately, for patients for whom the uncer-
tainty persisted. The false notion that trials (presented
here as the ethically most acceptable means to deal with
patient management uncertainties), must be interrupted
as soon as a convincing result is shown for the primary
hypothesis, is hopefully a soon-to-be archaic notion that
clinical research is foreign to medical care. The problem
is that once a trial like ISAT is interrupted, the commu-
nity of recruiting clinicians goes into hibernation, often
for many years, until the momentum is gathered anew
to launch another trial to address those questions which
emerge as soon as the initial trial results are published.
During this quiescent period, non-validated practices
and dogmas quickly take over the field, rendering the
process of trial initiation fearsomely difficult. We mustremember that clinical sciences differ from ‘pure’ sci-
ences, like physics: there are no universal laws; patient
outcomes are what matters, and care must constantly be
reappraised. The verdict of even a landmark trial does
not close the book on the subject matter. On the contrary,
it opens the door to multiple, more specific trial-able
questions. With this modern vision, properly designed
trials would provide optimal care in the presence of uncer-
tainty, and the role of the DSMBs would be modified. In-
stead of suggesting trial termination, they would suggest
interruption only for that one particular question, while
pointing out where the line of questioning of the ongoing
trial must continue. The current organization of clinical
research, which centers on singular questions addressed
one by one, should be replaced with a broader enterprise
embracing programs of a wider scope and aim. Once a
network of centers is well-organized and delivers reliable
answers to pertinent clinical questions, it should pursue a
more general goal: to provide transparent, optimal clinical
care, proposing randomized studies to all patients for
whom the results of an up-to-date randomized trial are
not available.
A single large trial or multiple small trials
One of the difficulties specific to our field is the relatively
small number, and heterogeneity of patients with rup-
tured intracranial aneurysms, which renders well-powered
randomized studies addressing specific questions difficult
to complete. To mitigate this difficulty, in the spirit of the
original ISAT study, we have chosen to keep inclusion cri-
teria broad. This choice of study design has two implica-
tions: the first is that at best, a general answer to the
question will be obtained, which can, at some future time,
be refined by other studies with more narrow inclusion
criteria. Although the overall number of patients for
whom the uncertainty persists is quite large (perhaps in
the range of 40% or more), the reasons why these patients
are not typical original ISAT cases are multiple and vari-
ous. For some clinicians, each individual reason (ie: giant
aneurysms, very small aneurysms) could be considered as
distinct research questions, and that ISAT-II combines
heterogeneous groups that they judge should not be
lumped into an overall outcome result, for fear of aver-
aging results that would normally pull in opposite direc-
tions. There may be no universally acceptable answer to
this problem. Others may fear that by the sheer force of
the law of large numbers differences in study population
may not be clearly highlighted in demographic statistics or
results and we may end up simply ‘repeating ISAT’. Except
for depriving patients from a treatment that would have
already been shown superior in a previous trial, a possibil-
ity that is explicitly excluded in the objectives and hypoth-
eses of ISAT II, what this concern amounts to in actual
practice remains unclear. We must, however, remember
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unjustified beliefs and hypotheses, and offer optimal care
in the presence of uncertainty [Raymond J, Darsaut TE,
Altman DG: Introducing care trials. J Clin Epidemiol
2012. Provisional acceptance]. From an organizational
perspective, it is easier to propose a single inclusive large
trial than to multiply small trials with narrow selection
criteria. It is possible, though, to pre-specify subgroups
that will separately be monitored by the DSMB. Thus, the
second implication of the ISAT II design choice is that the
DSMB must regularly be provided with subgroup-specific
safety data to ensure that an emerging obvious discrep-
ancy in clinical outcome will be addressed in a timely
manner in order to prevent additional patient morbidity.
A randomized context is the only way to firmly establish
that one particular treatment modality ought not to con-
tinue to be offered to a particular subgroup of patients.The preservation of surgical expertise to offer optimal
treatments to all patients
Since publication of ISAT results, neurovascular sur-
geons have increasingly been trained in endovascular
techniques [38]. As patients treated with surgical clip-
ping decreases, the open surgical expertise may become
difficult to acquire, and there is a real danger that it may
disappear altogether, as has virtually happened in some
areas in Europe. So-called minimally-invasive treatments
are not always safer, as has been recently borne out with
carotid stenting [39]. While hundreds of thousands of
patients were treated with this ‘minimally-invasive’ op-
tion, randomized trials comparing carotid stenting and
endarterectomy have repeatedly demonstrated a higher
incidence of stroke with stenting. In the same vein, there
is a risk that ruptured aneurysm patients today may be
treated with endovascular techniques while clipping
offers a safer, more effective alternative. While EVT
continues to be touted as the way ‘of the future’, there is
a real chance that it may not offer the best treatment
today. We must be careful to distinguish real progress,
with better patient outcomes, from self-fulfilling proph-
ecies; when neurosurgical aneurysm clipping is no longer
taught to trainees and high quality clipping skills are no
longer available, endovascular aneurysm treatments will
become the best treatment, but by default rather than
properly demonstrated merit. We owe it to patients to
continue the long and often difficult process of training
the next generation of neurovascular surgeons to practice
scientific medicine and to ensure that we abandon treat-
ment modalities only once alternatives have been proved
better in almost all if not all circumstances.Trial status
ISAT II is currently recruiting patients at several Canadian
centers, and the protocol is under ethics board review at
other international sites.
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